Retinoic acid receptor fusion proteins: Friend or foe

Molecular and Cellular Endocrinology

Volumn 165, Issue 1-2, 2000, Pages 1-6

  Breems De Ridder, Marleen C ^a   LÖwenberg, Bob ^a   Jansen, Joop H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Differentiation

Indexed keywords

HYBRID PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER SURVIVAL; CELL DIFFERENTIATION; DEACETYLATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TRANSACTIVATION;

HEMATOPOIESIS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; RECEPTORS, RETINOIC ACID; RECOMBINANT FUSION PROTEINS; TRANS-ACTIVATION (GENETICS); TRETINOIN;

EID: 0342656151     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(00)00255-0     Document Type: Article

References (48)

1. Arnould C., Philippe C., Bourdon V. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukemia. Hun. Mol. Genet. 8:1999;1741-1749.
2. Benedetti L., Levin A.A., Scicchitano B.M. et al. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood. 90:1997;1175-1185.
3. Bocchia M., Xu Q., Wesley U. et al. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leuk. Res. 21:1997;439-447.
4. van Bockstaele D.R., Lenjou M., Snoeck H.W., Lardon F., Stryckmans P., Peetermans M.E. Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+ BM cells. Ann. Hematol. 66:1993;61-66.
5. Bourgeut W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand binding domain of the human nuclear receptor RXRα Nature. 375:1995;377-382.
6. Brown D., Kogan S., Lagasse E. et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:1997;2551-2556.
7. Casini T., Pelicci P.G. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 18:1999;3235-3243.
8. Chen Z.C., Brand N.J., Chen A. et al. Fusion of a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J. 12:1993;1161-1167.
9. Cheng G.X., Zhu X.H., Men X.Q. et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc. Natl. Acad. Sci. USA. 96:1999;6318-6323.
10. ε). Blood. 90:1997;2987-2994.
11. Lo Coco F., Nervi C., Avvisati G., Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia. 12:1998;1866-1880.
12. Damm K., Heyman R.A., Umesono K., Evans R.M. Functional inhibition of retinoic acid response by dominant negative retinoic acid receptors mutants. Proc. Natl. Acad. Sci. USA. 90:1993;2989-2993.
13. Doucas V., Brockes J.P., Yaniv M., De The H., Dejean A. The PML-retinoic acid receptor α translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1. Proc. Natl. Acad. Sci. USA. 90:1993;9345-9349.
14. Dyck J.A., Maul G.G., Miller W.H. et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 76:1994;333-343.
15. Gratas C., Menot M.L., Dresch C., Chomienne C. Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. Leukemia. 7:1993;1156-1162.
16. Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 89:1997;376-387.
17. Guidez F., Huang W., Tong J.H. et al. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RARalpha patient. Leukemia. 8:1994;312-317.
18. Guignon F., De Bels F., Koken M., Feunteun J., Ameisen J.C., deThe H. PML induces a novel caspase-independent death process. Nat. Gen. 20:1998;259-265.
19. He L.Z., Tribioli C., Rivi R. et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc. Natl. Acad. Sci. USA. 94:1997;5302-5307.
20. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RAR alpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Gen. 18:1998;126-135.
21. He L.Z., Ivins S., Zelent A., Pandolfi P.P. Role of RARα-PLZF in the pathogenisis of acute promyelocytic leukemia. Blood. 92(Suppl 1):1998;480a.
22. Hess J.L., Korsemeyer S.J. Life, death and nuclear spots. Nat. Genet. 20:1998;220-222.
23. Jansen J.H., Mahfoudi A., Rambaud S., Lavau C., Wahli W., Dejean A. Multimeric complexes of the PML-retinoic acid receptor α fusion protein in acute promyelocytic leukaemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc. Natl. Acad. Sci. USA. 92:1995;7401-7405.
24. Jansen J.H., deRidder M.C., Geertsma W.M. et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood. 94:1999;39-45.
25. Kastner P., Mark M., Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life. Cell. 83:1995;859-869.
26. Koken M.H.M., Puvion-Dutilleul F., Guillemin M.C., Viron A. et al. The t(15;17) translocation alters a nuclear body in a retinoic acid reversible fashion. EMBO J. 13:1994;1073-1083.
27. Leid M., Kastner P., Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci. 17:1992;427-433.
28. Licht J.D., Chomienne C., Goy A. et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 85:1995;1083-1095.
29. Lin R.J., Egan D.A., Evans R.M. Molecular genetics of acute promyelocytic leukemia. TIG. 15:1999;179-184.
30. Linney E. Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation. Curr. Top. Dev. Biol. 27:1992;309-350.
31. Liu M., Iavarone A., Freedman L.P. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor: correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem. 271:1996;31723-31728.
32. Mandelli F., Diverio D., Avvisati G. et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 3:1997;1014-1021.
33. Melnick A., Licht J.D. Deconstructing a disease: RAR alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 93:1999;3167-3215.
34. Morosetti R., Park D.J., Chumakov A.M. et al. A novel, myeloid transcription factor, C/EBP α, is upregulated during granulocytic, but not monocytic, differentiation. Blood. 90:1997;2591-2600.
35. Park D.J., Chumakov A.M., Voung P.T. et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J. Clin. Invest. 103:1999;1399-1408.
36. Perez A., Kastner P., Sethi S., Lutz Y., Reibel C., Chambon P. PML-RAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J. 12:1993;3171-3182.
37. Purton L.E., Bernstein I.D., Collins S.J. All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed granulocyte/monocyte progenitors. Blood. 94:1999;483-495.
38. Redner R.L., Corey S.J., Rush E.A. Differentiation of t(5;17) variant acute promyelocytic leukemia blasts by all-trans retinoic acid. Leukemia. 11:1997;1014-1016.
39. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigns. Blood. 94:1999;417-428.
40. Renaud J.-P., Rochel N., Ruff M. et al. Crystal structure of the RAR-α ligand binding domain bound to all-trans retinoic acid. Nature. 278:1995;681-689.
41. Tallman M.S., Andersen J.W., Schiffer C.A. All-trans-retinoic acid in acute promyelocytic leukemia. New Eng. J. Med. 337:1997;1021-1028.
42. Tsai S., Bartelmez S., Heyman R.A. et al. A mutated retinoic acid receptor α exhibiting dominant-negative activity alters the lineage development of a multipotent hematopietic cell line. Gen. Dev. 6:1992;2258-2269.
43. Tsai S., Bartelmez S., Sitnicka E., Collins S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev. 8:1994;2831-2841.
44. Wang Z.G., Delva L., Gaboli M. et al. Role of PML in cell growth and the retinoic acid pathway. Science. 279:1998;1547-1551.
45. Wang Z.-G., Rego E., Peruzzi D., He L.Z., Pandolfi P.P. Loss of PML function enhances the frequency and onset of APL in PML-RARα transgenic mice. Blood. 92(2):1998b;479a.
46. Wells R.A., Hummel J.L., Dekoven A. et al. A new variant translocation in acute promyelocytic leukemia: molecular characterization and clinical correlation. Leukemia. 10:1996;735-740.
47. Weiss K., Rambaud S., Lavau C. et al. Retinoic acid regulates aberrant nuclear localisation of PML-RAR α in acute promyelocytic leukaemia cells. Cell. 76:1994;345-356.
48. Zhong S., Delva L., Rachez C. et al. A RA-dependent tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins. Nat. Genet. 23:1999;287-295.